PRTK - Paratek Pharmaceuticals, Inc.
After hours:
| Previous Close | 2.1950 |
| Open | 2.2000 |
| Bid | 2.1700 x 41800 |
| Ask | 2.1800 x 42300 |
| Day's Range | 2.1700 - 2.2004 |
| 52 Week Range | 1.2900 - 3.6500 |
| Volume | |
| Avg. Volume | 1,138,369 |
| Market Cap | 129.458M |
| Beta (5Y Monthly) | 1.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1700 |
| Earnings Date | Aug 01, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Oct 31, 2014 |
| 1y Target Est | 3.10 |
GlobeNewswireParatek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings
Transaction Provides Paratek Shareholders with Immediate Value and Liquidity Reflects Potential Value of $3.00 per Share of Common Stock, Including Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 on Achievement of a Commercial Milestone Total Transaction Consideration of up to Approximately $462 Million BOSTON and CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company
Simply Wall St.Paratek Pharmaceuticals (NASDAQ:PRTK) investors are sitting on a loss of 83% if they invested five years ago
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...
- Thomson Reuters StreetEvents
Q1 2023 Paratek Pharmaceuticals Inc Earnings Call
Q1 2023 Paratek Pharmaceuticals Inc Earnings Call
ZacksParatek Pharmaceuticals (PRTK) Reports Q1 Loss, Misses Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of 7.89% and 1.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022 -- Company Reiterates Full-Year Revenue Guidance of $143 to $158 Million -- Announces Full-Year R&D and SG&A Expense Guidance of $160 to $170 Million, Approximately $20 Million in Savings Over Annualized Fourth Quarter 2022 Spend Rate1, Enabled by Operational Efficiencies BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK)
- GlobeNewswire
Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report financial results for first quarter 2023.The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com.Domestic investors wishing to participate in the call will dial: 800-920-3371 and internation
- Simply Wall St.
There's No Escaping Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) Muted Revenues Despite A 77% Share Price Rise
Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) shareholders would be excited to see that the share price has had a great...
- GlobeNewswire
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that new data from studies with NUZYRA® (omadacycline) will be presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). The hybrid
- Thomson Reuters StreetEvents
Q4 2022 Paratek Pharmaceuticals Inc Earnings Call
Q4 2022 Paratek Pharmaceuticals Inc Earnings Call
ZacksParatek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of -1,300% and 33.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year -- Continued Progress on the Rare Disease Nontuberculous Mycobacteria (NTM) & BARDA Project BioShield Anthrax Programs BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2022. Paratek gene
- GlobeNewswire
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16
BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, March 16, 2023 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full year 2022. The audio webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.ParatekPharma.com. Domestic investors wishing to
- GlobeNewswire
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on February 28, 2023, the Company granted stock options and restricted stock units to four new employees of the Company. These awards were granted pursuant to t
- Simply Wall St.
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) On The Verge Of Breaking Even
With the business potentially at an important milestone, we thought we'd take a closer look at Paratek Pharmaceuticals...
- GlobeNewswire
Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)
National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure InfectionsBOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China’s National Healthcare Security Administration (NHSA) has added the intravenous (IV) formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL) for treatment of community-acquir
- GlobeNewswire
Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract
Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022Procurement Triggered by Positive Top-Line Data from Pilot Efficacy Study of NUZYRA for the Treatment of Pulmonary Anthrax Announced in December BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced the receipt of a $36.4 million milestone payment associated with the second procurement of NUZYRA® (omadacycline) under the company’s Project BioShield contract w
- Simply Wall St.
Individual investors account for 39% of Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) ownership, while institutions account for 38%
If you want to know who really controls Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ), then you'll have to look at the...
- GlobeNewswire
Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board
BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company’s independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022. Dr. Stein was selected unanimously by the independent directors of the Board, in recognition of his extensive leadership experience, in-depth knowledge of Paratek and the business of the anti-infective industry, strong financial and operation
- GlobeNewswire
Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield
100% Survival Rate in Anthrax-infected Rabbits Treated with OmadacyclineTotal Revenue Recognition to Paratek of $38.1 Million BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s effectiveness in the treatment of pulmonary anthrax. In the study, a 100% survival rate was observed in omadacycline-treated rabbits at the specified endpoint of 35-45 days post Bacillus anthra
- GlobeNewswire
Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that Evan Loh, M.D., chief executive officer, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30 at 9:15 a
- Simply Wall St.
Paratek Pharmaceuticals Third Quarter 2022 Earnings: Misses Expectations
Paratek Pharmaceuticals ( NASDAQ:PRTK ) Third Quarter 2022 Results Key Financial Results Revenue: US$30.2m (up 24% from...
ZacksParatek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of -40.74% and 13.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.5 Million from the Core Commercial Business, a 31% increase from $19.4 Million in Third Quarter 2021 -- Initiated Rabbit Pilot Efficacy Study for the Treatment of Pulmonary Anthrax -- Announced Commercial Availability of U.S.-manufactured NUZYRA Tablets BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the quarter ende
- GlobeNewswire
Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announces that Evan Loh, M.D., chief executive officer, will present at the Credit Suisse 31st Annual Healthcare Conference held Nov. 7-10.Dr. Loh’s presentation will be available on
- GlobeNewswire
Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces the commercial availability of U.S.-produced NUZYRA® (omadacycline) tablets. This milestone follows a successful technology transfer by Paratek and its tablet manufacturing partners in the United States and Europe. NUZYRA is the company’s broad-spectrum, novel antibiotic available in both intravenous and oral formulations. Onshoring of the manufacturing process for the tablets is the first comp